Gain Therapeutics to Hold Virtual KOL Event Focused on GT-02287 for Parkinson's Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 08 2025
0mins
Source: Globenewswire
KOL Event Announcement: Gain Therapeutics will host a virtual event on October 14, 2025, featuring experts discussing biomarkers and clinical endpoints related to their drug candidate GT-02287 for Parkinson's disease.
Clinical Trial Updates: GT-02287 is currently in a Phase 1b trial, showing promising safety and tolerability results, with potential disease-modifying effects in preclinical models of Parkinson's disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
